NCT06689085 Phase 3 Recruiting
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism Study sponsor: Halozyme Therapeutics
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2028-03 Estimated
Enrollment · participants 100 Estimated
Source updated 2026-02-18 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology